These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31450229)

  • 1. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Cardiorenal Med; 2019; 9(6):400-407. PubMed ID: 31450229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis.
    Toth PP; Philip S; Hull M; Granowitz C
    Clin Cardiol; 2019 Oct; 42(10):908-913. PubMed ID: 31368589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Vasc Health Risk Manag; 2019; 15():533-538. PubMed ID: 31824165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk.
    Toth PP; Granowitz C; Hull M; Liassou D; Anderson A; Philip S
    J Am Heart Assoc; 2018 Aug; 7(15):e008740. PubMed ID: 30371242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.
    Toth PP; Granowitz C; Hull M; Anderson A; Philip S
    Lipids Health Dis; 2019 Sep; 18(1):175. PubMed ID: 31526399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    J Clin Lipidol; 2019; 13(1):100-108. PubMed ID: 30594443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
    Nichols GA; Philip S; Reynolds K; Granowitz CB; Fazio S
    Diabetes Obes Metab; 2019 Feb; 21(2):366-371. PubMed ID: 30225881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database.
    Toth PP; Hull M; Granowitz C; Philip S
    Future Cardiol; 2021 Jul; 17(4):743-755. PubMed ID: 33275042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database.
    Sazonov V; Beetsch J; Phatak H; Wentworth C; Evans M
    Atherosclerosis; 2010 Jan; 208(1):210-6. PubMed ID: 19766999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.
    Case BC; Bress AP; Kolm P; Philip S; Herrick JS; Granowitz CB; Toth PP; Fan W; Wong ND; Hull M; Weintraub WS
    J Clin Lipidol; 2019; 13(5):754-761. PubMed ID: 31427271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
    Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.